keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
L524-0366 ([1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone) 是一种 TWEAK-Fn14 信号级联抑制剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,297 | 现货 | ||
2 mg | ¥ 1,939 | 现货 | ||
5 mg | ¥ 2,927 | 现货 | ||
10 mg | ¥ 4,388 | 现货 | ||
25 mg | ¥ 7,320 | 现货 | ||
50 mg | ¥ 9,870 | 现货 | ||
100 mg | ¥ 13,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,770 | 现货 |
产品描述 | L524-0366 ([1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone) is a TWEAK-Fn14 signaling cascade inhibitor. |
体外活性 | L524-0366 mitigated maladaptive remodeling with TAC. TWEAK induced secretion of the pro-inflammatory chemokine, monocyte chemoattractant protein 1 from WT but not Fn14-/-?fibroblasts in vitro, in part through activation of non-canonical NF-κB signaling. Finally, Fn14 expression was increased in mouse following TAC and in human failing hearts. |
细胞实验 | Wild type (WT) and Fn14 knock out (Fn14-/-) mice were subjected to pressure overload [transaortic constriction (TAC)] for 1 or 6 weeks. A subset of WT TAC animals were treated with the Fn14 antagonist L524-0366. Cardiac function was measured by echocardiography. Cardiac fibrosis and macrophage infiltration were quantified using immunohistochemistry and flow cytometry, respectively. Cardiac fibroblasts were isolated for quantifying TWEAK-induced chemokine release. |
别名 | [1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone |
分子量 | 308.79 |
分子式 | C13H13ClN4OS |
CAS No. | 951612-19-4 |
keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.09 mg/mL (10 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.2384 mL | 16.1922 mL | 32.3845 mL | 80.9612 mL |
5 mM | 0.6477 mL | 3.2384 mL | 6.4769 mL | 16.1922 mL | |
10 mM | 0.3238 mL | 1.6192 mL | 3.2384 mL | 8.0961 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
L524-0366 951612-19-4 Others L524 0366 [1-(3-chlorophenyl)triazol-4-yl]-thiomorpholino-methanone L5240366 L-524-0366 Inhibitor inhibitor inhibit